代谢功能障碍相关的稳定性肝病和稳定性肝炎的多基因风险评分:叙述性审查
Tatsuo Kanda1,2, Reina Sasaki-Tanaka2, Hiroyuki Abe2
1Division of Gastroenterology and Hepatology, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, Uonuma Kikan Hospital, Minamiuonuma 949-7302, Japan.
像PNPLA3这样的遗传变异显著增加了与代谢功能障碍相关的脂肪性肝病 (MASLD) 和相关并发症的风险. 多基因风险评分 (PRS) 可以更好地预测MASLD和MASH的进展.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 遗传学 遗传学是一种遗传学.
- 个性化医疗是个性化的医疗.
背景情况:
- 与代谢功能障碍相关的脂肪性肝病 (MASLD) 和与代谢功能障碍相关的脂肪性肝炎 (MASH) 是导致肝硬化和肝细胞癌 (HCC) 的主要原因.
- 对于MASLD和MASH患者,迫切需要有效的查和管理策略.
研究的目的:
- 审查与MASLD和MASH病原体相关的遗传变异.
- 评估多基因风险评分 (PRS) 在预测MASLD,MASH,肝硬化和HCC方面的有用性.
- 突出遗传易感性在肝病个性化医疗中的作用.
主要方法:
- 现有文献的叙述性审查.
- 对遗传变异的分析 (例如PNPLA3,TM6SF2,GCKR,MBOAT7,MERTK,HSD17B13) 进行分析.
- 评估多基因风险评分 (PRS) 作为预测标记.
主要成果:
- PNPLA3基因变异与MASLD,MASH,肝硬化和HCC的致病性增加有着强烈的关联.
- 多基因风险评分 (PRS) 与单核酸多态相比,对MASLD,MASH,肝硬化和HCC的预测能力更强.
- 针对遗传变异的治疗策略 (例如PNPLA3的RNA干扰) 正在开发中.
结论:
- 遗传易感性,特别是PRS,是MASLD和MASH的关键预测标记.
- 结合遗传洞察力的个性化医疗方法对于未来的患者管理至关重要.
- 跨学科的合作对于解决MASLD和MASH中复杂的挑战至关重要.
更多相关视频
07:12Author Spotlight: Analysis of Fluorescent-Stained Lipid Droplets with 3D Reconstruction for Hepatic Steatosis Assessment
Published on: June 2, 2023
07:03Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
相关概念视频
Liver Physiology
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can also...
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS):
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Cirrhosis II: Pathophysiology
